# Cemtrex Inc: financial statements, quarterly

CETX · Nasdaq · CIK 1435064 · [Industrials](/sectors/industrials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/cetx.md) · [Financials](/companies/cetx/financials.md) · [Filings](/companies/cetx/filings.md) · [Insiders](/companies/cetx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cetx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.6 d](/filings/0001493152-24-052491.md) | [16.9](/filings/0001493152-25-006882.md) | [17.2](/filings/0001641172-25-010564.md) | [14.7](/filings/0001493152-25-011969.md) | [18.1 d](/filings/0001493152-25-029383.md) | [13.7](/filings/0001493152-26-007122.md) | [27.3](/filings/0001493152-26-023803.md) | [17.0](/filings/0001493152-26-038337.md) | [18.5 d](/filings/0001493152-25-029383.md) | [16.1](/filings/0001493152-26-007122.md) | [18.1](/filings/0001493152-26-023803.md) | [18.4](/filings/0001493152-26-038337.md) |
| Cost of revenue | $m | [9.8 d](/filings/0001493152-24-052491.md) | [9.8](/filings/0001493152-25-006882.md) | [10.2](/filings/0001641172-25-010564.md) | [8.8](/filings/0001493152-25-011969.md) | [10.6 d](/filings/0001493152-25-029383.md) | [8.0](/filings/0001493152-26-007122.md) | [15.1](/filings/0001493152-26-023803.md) | [9.6](/filings/0001493152-26-038337.md) | [11.5 d](/filings/0001493152-25-029383.md) | [10.5](/filings/0001493152-26-007122.md) | [11.2](/filings/0001493152-26-023803.md) | [10.7](/filings/0001493152-26-038337.md) |
| Gross profit | $m | [6.8 d](/filings/0001493152-24-052491.md) | [7.1](/filings/0001493152-25-006882.md) | [6.9](/filings/0001641172-25-010564.md) | [5.9](/filings/0001493152-25-011969.md) | [7.6 d](/filings/0001493152-25-029383.md) | [5.7](/filings/0001493152-26-007122.md) | [12.2](/filings/0001493152-26-023803.md) | [7.4](/filings/0001493152-26-038337.md) | [7.1 d](/filings/0001493152-25-029383.md) | [5.6](/filings/0001493152-26-007122.md) | [6.8](/filings/0001493152-26-023803.md) | [7.7](/filings/0001493152-26-038337.md) |
| Research and development | $m | [(0.6) d](/filings/0001493152-24-052491.md) | [0.8](/filings/0001493152-25-006882.md) | [1.0](/filings/0001641172-25-010564.md) | [0.9](/filings/0001493152-25-011969.md) | [0.7 d](/filings/0001493152-25-029383.md) | [0.9](/filings/0001493152-26-007122.md) | [0.8](/filings/0001493152-26-023803.md) | [0.4](/filings/0001493152-26-038337.md) | [0.3 d](/filings/0001493152-25-029383.md) | [0.5](/filings/0001493152-26-007122.md) | [0.5](/filings/0001493152-26-023803.md) | [0.4](/filings/0001493152-26-038337.md) |
| Selling, general and administrative | $m | [7.1 d](/filings/0001493152-24-052491.md) | [6.6](/filings/0001493152-25-006882.md) | [6.7](/filings/0001641172-25-010564.md) | [7.9](/filings/0001493152-25-011969.md) | [6.4 d](/filings/0001493152-25-029383.md) | [6.8](/filings/0001493152-26-007122.md) | [6.5](/filings/0001493152-26-023803.md) | [7.3](/filings/0001493152-26-038337.md) | [7.7 d](/filings/0001493152-25-029383.md) | [7.6](/filings/0001493152-26-007122.md) | [8.0](/filings/0001493152-26-023803.md) | [7.9](/filings/0001493152-26-038337.md) |
| Operating income | $m | [(0.0) d](/filings/0001493152-24-052491.md) | [(0.7)](/filings/0001493152-25-006882.md) | [(1.0)](/filings/0001641172-25-010564.md) | [(3.2)](/filings/0001493152-25-011969.md) | [(0.3) d](/filings/0001493152-25-029383.md) | [(2.3)](/filings/0001493152-26-007122.md) | [4.6](/filings/0001493152-26-023803.md) | [(0.6)](/filings/0001493152-26-038337.md) | [(1.2) d](/filings/0001493152-25-029383.md) | [(2.8)](/filings/0001493152-26-007122.md) | [(2.2)](/filings/0001493152-26-023803.md) | [(1.2)](/filings/0001493152-26-038337.md) |
| Interest expense | $m | [1.2 d](/filings/0001493152-23-046365.md) | [0.6](/filings/0001493152-24-006268.md) | [0.6](/filings/0001493152-24-019239.md) | [0.5](/filings/0001493152-25-011969.md) | [0.5 d](/filings/0001493152-25-029383.md) | [0.5](/filings/0001493152-26-007122.md) | [0.5](/filings/0001493152-26-023803.md) | [0.5](/filings/0001493152-26-038337.md) | [0.7 d](/filings/0001493152-25-029383.md) | [12.1](/filings/0001493152-26-007122.md) | [0.6](/filings/0001493152-26-023803.md) | [1.1](/filings/0001493152-26-038337.md) |
| Income tax | $m | [0.4 d](/filings/0001493152-24-052491.md) | [0.1](/filings/0001493152-25-006882.md) | [0.1](/filings/0001641172-25-010564.md) | [0.1](/filings/0001493152-25-011969.md) | [(0.0) d](/filings/0001493152-25-029383.md) | [0.1](/filings/0001493152-26-007122.md) | [0.1](/filings/0001493152-26-023803.md) | [0.0](/filings/0001493152-26-038337.md) | [0.5 d](/filings/0001493152-25-029383.md) | [0.3](/filings/0001493152-26-007122.md) | [0.1](/filings/0001493152-26-023803.md) | [(0.1)](/filings/0001493152-26-038337.md) |
| Net income | $m | [6.5 d](/filings/0001493152-25-011969.md) | [(1.2)](/filings/0001493152-25-011969.md) | [(1.5)](/filings/0001493152-25-011969.md) | [(9.0)](/filings/0001493152-25-011969.md) | [4.4 d](/filings/0001493152-26-023803.md) | [(28.8)](/filings/0001493152-26-038337.md) | [8.6](/filings/0001493152-26-038337.md) | [(4.6)](/filings/0001493152-26-038337.md) | [(3.2) d](/filings/0001493152-26-023803.md) | [(20.6)](/filings/0001493152-26-038337.md) | [0.9](/filings/0001493152-26-038337.md) | [(4.5)](/filings/0001493152-26-038337.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(5.21)](/filings/0001493152-26-038337.md) | not reported | not reported | not reported | [(3.27)](/filings/0001493152-26-038337.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(5.21)](/filings/0001493152-26-038337.md) | not reported | not reported | not reported | [(3.27)](/filings/0001493152-26-038337.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | period not labelled (2025-05-15) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.8](/filings/0001493152-25-006882.md) | [2.9](/filings/0001641172-25-010564.md) | [6.5](/filings/0001493152-25-011969.md) | [3.9](/filings/0001493152-25-029383.md) | [4.2](/filings/0001493152-26-007122.md) | [4.5](/filings/0001493152-26-023803.md) | not reported | [7.0](/filings/0001493152-26-038337.md) | [5.0](/filings/0001493152-26-038337.md) | [20.5](/filings/0001493152-26-007122.md) | [6.6](/filings/0001493152-26-023803.md) | [8.0](/filings/0001493152-26-038337.md) |
| Current assets | $m | [26.4](/filings/0001493152-24-006268.md) | [28.4](/filings/0001493152-24-019239.md) | [26.4](/filings/0001493152-24-032245.md) | [26.7](/filings/0001493152-25-029383.md) | [29.0](/filings/0001493152-25-006882.md) | [28.6](/filings/0001641172-25-010564.md) | not reported | [29.3](/filings/0001493152-25-011969.md) | [29.0](/filings/0001493152-26-038337.md) | [42.7](/filings/0001493152-26-007122.md) | [37.9](/filings/0001493152-26-023803.md) | [37.5](/filings/0001493152-26-038337.md) |
| Total assets | $m | [45.3](/filings/0001493152-24-006268.md) | [47.2](/filings/0001493152-24-019239.md) | [43.8](/filings/0001493152-24-032245.md) | [44.1](/filings/0001493152-25-029383.md) | [46.7](/filings/0001493152-25-006882.md) | [46.2](/filings/0001641172-25-010564.md) | not reported | [47.0](/filings/0001493152-25-011969.md) | [47.8](/filings/0001493152-26-038337.md) | [60.3](/filings/0001493152-26-007122.md) | [70.7](/filings/0001493152-26-023803.md) | [70.0](/filings/0001493152-26-038337.md) |
| Current liabilities | $m | [28.7](/filings/0001493152-24-006268.md) | [18.1](/filings/0001493152-24-019239.md) | [14.0](/filings/0001493152-24-032245.md) | [18.6](/filings/0001493152-25-029383.md) | [24.9](/filings/0001493152-25-006882.md) | [23.6](/filings/0001641172-25-010564.md) | not reported | [24.4](/filings/0001493152-25-011969.md) | [23.8](/filings/0001493152-26-038337.md) | [18.0](/filings/0001493152-26-007122.md) | [24.2](/filings/0001493152-26-023803.md) | [24.3](/filings/0001493152-26-038337.md) |
| Total liabilities | $m | [38.0](/filings/0001493152-24-006268.md) | [42.1](/filings/0001493152-24-019239.md) | [43.5](/filings/0001493152-24-032245.md) | [39.2](/filings/0001493152-25-029383.md) | [48.2](/filings/0001493152-25-006882.md) | [39.5](/filings/0001641172-25-010564.md) | not reported | [43.1](/filings/0001493152-25-011969.md) | [39.1](/filings/0001493152-26-038337.md) | [31.2](/filings/0001493152-26-007122.md) | [36.0](/filings/0001493152-26-023803.md) | [38.0](/filings/0001493152-26-038337.md) |
| Long-term debt | $m | not reported | [21.6](/filings/0001493152-24-019239.md) | [16.9](/filings/0001493152-24-032245.md) | [13.3](/filings/0001493152-25-029383.md) | [11.9](/filings/0001493152-25-006882.md) | [9.5](/filings/0001641172-25-010564.md) | not reported | [8.5](/filings/0001493152-25-011969.md) | [4.6](/filings/0001493152-26-038337.md) | [8.0](/filings/0001493152-26-007122.md) | [8.8](/filings/0001493152-26-023803.md) | [8.6](/filings/0001493152-26-038337.md) |
| Current portion of debt | $m | [15.7](/filings/0001493152-24-006268.md) | [0.9](/filings/0001493152-24-019239.md) | [0.7](/filings/0001493152-24-032245.md) | [4.7](/filings/0001493152-25-029383.md) | [6.7](/filings/0001493152-25-006882.md) | [9.3](/filings/0001641172-25-010564.md) | not reported | [9.8](/filings/0001493152-25-011969.md) | [8.9](/filings/0001493152-26-038337.md) | [4.7](/filings/0001493152-26-007122.md) | [8.8](/filings/0001493152-26-023803.md) | [8.1](/filings/0001493152-26-038337.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.8](/filings/0001493152-25-011969.md) | [4.7](/filings/0001493152-25-011969.md) | [0.0](/filings/0001493152-25-011969.md) | [4.7](/filings/0001493152-26-038337.md) | [(1.6)](/filings/0001493152-26-038337.md) | [6.7](/filings/0001493152-26-038337.md) | [6.4](/filings/0001493152-25-029383.md) | [3.9](/filings/0001493152-26-038337.md) | [8.7](/filings/0001493152-26-038337.md) | [29.1](/filings/0001493152-26-038337.md) | [34.7](/filings/0001493152-26-038337.md) | [32.0](/filings/0001493152-26-038337.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [686 d](/filings/0001493152-24-052491.md) | [(3,139)](/filings/0001493152-25-006882.md) | [387 d](/filings/0001641172-25-010564.md) | [676 d](/filings/0001493152-25-011969.md) | [(1,873) d](/filings/0001493152-25-029383.md) | [(1,202)](/filings/0001493152-26-007122.md) | [2,802 d](/filings/0001493152-26-023803.md) | [1,810 d](/filings/0001493152-26-038337.md) | [(3,251) d](/filings/0001493152-25-029383.md) | [(892)](/filings/0001493152-26-007122.md) | [(4,419) d](/filings/0001493152-26-023803.md) | [410 d](/filings/0001493152-26-038337.md) |
| Capital expenditure | $k | [2,000 d](/filings/0001493152-24-052491.md) | [291](/filings/0001493152-25-006882.md) | [64.6 d](/filings/0001641172-25-010564.md) | [74.0 d](/filings/0001493152-25-011969.md) | [868 d](/filings/0001493152-25-029383.md) | [924](/filings/0001493152-26-007122.md) | [436 d](/filings/0001493152-26-023803.md) | [75.8 d](/filings/0001493152-26-038337.md) | [496 d](/filings/0001493152-25-029383.md) | [184](/filings/0001493152-26-007122.md) | [153 d](/filings/0001493152-26-023803.md) | [630 d](/filings/0001493152-26-038337.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.8](/filings/0001493152-24-006268.md) | [0.8](/filings/0001493152-24-019239.md) | [0.9](/filings/0001493152-24-032245.md) | [0.0](/filings/0001493152-25-006882.md) | [0.0](/filings/0001641172-25-010564.md) | [0.0](/filings/0001493152-25-011969.md) | [0.1](/filings/0001493152-26-007122.md) | [0.4](/filings/0001493152-26-023803.md) | [0.9](/filings/0001493152-26-038337.md) | [2.6](/filings/0001493152-26-007122.md) | [10.2](/filings/0001493152-26-023803.md) | [1.4](/filings/0001493152-26-038337.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,721,141 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038337.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.